Trial Profile
A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Bronchitis; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms M-34273-46
- Sponsors AstraZeneca; AstraZeneca AB
- 24 May 2017 Results of a post-hoc analysis assessing the efficacy of aclidinium bromide on cough-related endpoints in symptomatic patients with moderate COPD, stratified according to cough severity, presented at the 113th International Conference of the American Thoracic Society.
- 24 May 2017 Primary endpoint has been met. (Change From Baseline in Overall Exacerbations of Chronic Pulmonary Disease Tool-Respiratory Symptoms (E-RS) Total Score Over the 8 Week Study Period), as reported in an abstract presented at the 113th International Conference of the American Thoracic Society
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society